Compliance software built for Regenerative Medicine Clinics
Regenerative medicine is where this compliance category was born. Stem cell and regen marketing have drawn a large share of FDA warning letters over the years.
Why this specialty gets extra attention
Regenerative medicine is the specialty that shaped much of today's FDA enforcement on healthcare marketing. FTC settlements over social-media stem cell claims, the Kimera Labs exosome case, and ongoing FDA CBER attention on HCT/P products have each set precedent for how every regen clinic's marketing is read. Our rule set started with this specialty, and we built it first for regen clinics.
Active enforcement
What regulators are actually doing
FDA warning letters, FTC settlements, and state board actions that shape marketing rules for regenerative medicine clinics.
FTC and state actions over social-media stem cell claims
The FTC and state attorneys general have taken action against stem cell clinics over social-media claims that treatments could cure arthritis, heal spinal cord injury, or reverse aging. Outcomes in this area have included refunds to patients, long-term compliance monitoring, and orders to stop repeating the claims. A single post can be enough to start an investigation.
FDA warning letters on 'FDA-approved stem cell' language
The FDA has issued a sustained campaign of warning letters on language implying FDA approval of HCT/P products. 'FDA-approved stem cells,' 'FDA-approved treatment,' and variations remain among the most-cited phrases in active enforcement.
FDA CBER actions on HCT/P marketing outside the 361 pathway
HCT/P products are regulated under CBER with a specific pathway for minimal-manipulation, homologous-use products. Marketing products outside this pathway as 'minimally manipulated' or 'homologous use' - or making therapeutic claims that push the product into the 351 (drug/biologic) pathway - has produced warning letters to clinics and lab partners.
FTC actions on exosome marketing
Exosome marketing has drawn particular FTC attention. Claims that exosomes 'repair,' 'regenerate,' or 'heal' tissue - standard language in exosome marketing a few years ago - are now specific enforcement targets.
State AG actions on regen clinic consumer protection
Beyond FDA and FTC, state Attorneys General have used consumer protection authority to pursue regen clinics. Texas, California, and New York have each brought actions based on the intersection of state consumer protection and healthcare marketing.
Specialty-specific phrase library
Risky phrases we catch (and lower-risk alternatives)
Each phrase below reflects patterns regulators have flagged. RegenCompliance catches them automatically on every scan, with a lower-risk alternative ready.
Higher-risk wording
“FDA-approved stem cells”
Why: Most HCT/P products are not FDA-approved. The phrase is the single most-cited in regen enforcement.
Lower-risk rewrite
“Performed in an FDA-registered facility using HCT/P materials under the 361 pathway”
Higher-risk wording
“Cures arthritis”
Why: Disease cure claim - direct FDA enforcement target going back to the 2010s.
Lower-risk rewrite
“May support joint comfort and function for some patients”
Higher-risk wording
“Heals damaged tissue”
Why: Therapeutic efficacy claim that pushes product into drug-regulatory pathway.
Lower-risk rewrite
“Some patients report improvement in function and comfort in the treated area”
Higher-risk wording
“Reverses aging”
Why: An active FTC enforcement target in stem cell marketing.
Lower-risk rewrite
“May support aspects of skin and tissue health in the treated area”
Higher-risk wording
“Guaranteed results”
Why: Guarantee claim is almost never substantiable for regenerative therapies.
Lower-risk rewrite
“Outcomes vary; we discuss realistic expectations during every consultation”
Higher-risk wording
“Proven to regrow cartilage”
Why: Tissue regeneration claim subject to FDA CBER scrutiny and FTC substantiation rules.
Lower-risk rewrite
“Clinical studies on [specific protocol] have shown [specific endpoint]; patient outcomes vary”
Higher-risk wording
“Exosomes repair damaged cells”
Why: Current FTC target; 'repair' claims on exosomes are under active enforcement.
Lower-risk rewrite
“Research into exosome biology continues; our current protocols use [product] for [appropriate indication]”
Higher-risk wording
“100% safe, no side effects”
Why: Absolute safety claim conflicts with clinical reality and substantiation rules.
Lower-risk rewrite
“Adverse events are rare but possible; candidacy and risks are discussed at consultation”
Higher-risk wording
“Alternative to surgery”
Why: Comparative claim implies equivalence to surgical outcomes without substantiation.
Lower-risk rewrite
“A non-surgical option some patients choose to explore before considering surgery”
Higher-risk wording
“Works for all patients”
Why: Universal efficacy claim is not substantiable for any regenerative protocol.
Lower-risk rewrite
“May be appropriate for patients who meet specific candidacy criteria discussed at consultation”
Higher-risk wording
“Treats spinal cord injury”
Why: Direct disease/condition treatment claim on HCT/P products is an FDA target.
Lower-risk rewrite
“(Remove entirely - no compliant reframe for direct spinal-cord-injury treatment claims)”
Higher-risk wording
“Breakthrough therapy”
Why: 'Breakthrough therapy' is a specific FDA designation; misuse is a direct flag.
Lower-risk rewrite
“An emerging area of regenerative treatment we are offering based on current evidence”
You’ve probably said this
Here’s a lower-risk way to say it.
These are phrases regenerative medicine clinics have actually said (or considered saying). Each one triggers a specific FDA, FTC, or state board rule. Tap to see the rule and the rewrite.
On every scan
What we catch that generic tools miss
Stem cell service page claims beyond the 361 pathway
Many regen clinic service pages describe treatments using language that would push the product into the 351 (drug/biologic) pathway. Our scanner is specifically trained on the pathway distinctions - it flags language that implies the regulatory category you are not operating under.
Testimonials describing disease-specific outcomes
Testimonials that name specific conditions ('my arthritis is gone,' 'I can walk again after my stem cell treatment') carry the disease claim into your marketing via the endorsement. Our scanner catches this pattern - which is what triggered several recent enforcement actions.
Social media content from staff personal accounts
Staff personal accounts reposting clinic outcomes, partner content, or general regen marketing often contain language that the clinic's main website has already been cleaned up to avoid. Regulators do not distinguish between the clinic's official account and a physician's personal one.
Content partnerships with equipment or biologic suppliers
Supplier-provided marketing assets (typically written for clinician education rather than consumer marketing) frequently contain language that the supplier itself would not use in consumer-facing channels. Our scanner catches reused supplier content with the specific problem phrases.
Conference or webinar recordings posted publicly
Internal-audience or clinician-audience content (conferences, CE-credit talks, peer presentations) uses a different standard than consumer marketing. Posting these recordings publicly without review often puts clinical-discussion language into a consumer-marketing surface, which is where compliance issues enter.
Case study
A typical first scan on a regenerative medicine clinic homepage
“Our revolutionary stem cell therapy cures arthritis and heals damaged tissue using FDA-approved stem cells. Exosomes repair damaged cells with 100% safe, no side effects - guaranteed results to regrow cartilage and reverse aging. Works for all patients - a proven alternative to surgery for spinal cord injury, joint pain, and chronic conditions.”
“Our regenerative medicine offerings are performed in an FDA-registered facility using HCT/P materials under the 361 pathway. Some patients report improvement in joint comfort and function in the treated area; outcomes vary and candidacy is discussed during every consultation. Adverse events are rare but possible and are reviewed at consultation. A non-surgical option some patients choose to explore before considering surgery. Clinical studies continue to inform our protocols; results depend on many factors specific to each patient.”
Outcome
Score went from 8 to 89 across 14 flagged phrases. PDF audit trail generated covering every rewrite. Every core service offering preserved - language reframed to match the 361 regulatory pathway and current FTC enforcement patterns.
Why RegenCompliance vs. generic tools
Regenerative medicine is the specialty that defined this category of enforcement. More rules in our rule set come from stem cell, PRP, and exosome warning letters than from any other specialty. If you run a regen clinic, this is not a generic compliance tool you are getting - it is a compliance tool that was primarily built around your specialty, with every major enforcement action in your space already encoded as a rule.
Who uses this
Built for every practice type in this specialty
Evaluating alternatives?
How RegenCompliance compares for regenerative medicine clinics
Tools in the platform
What you actually get for regenerative medicine clinics
Compliance Scanner
Regenerative Medicine Clinics-specific rule calibration. Flags disease claims, FDA misuse, and specialty-specific patterns.
Learn moreAI Compliant Rewriter
Turn flagged regenerative medicine clinics claims into lower-risk alternatives that preserve your voice.
Learn moreAudit Trail + PDF Export
A clear record of your pre-publish review, ready to save to your files.
Learn moreFAQ
Regenerative Medicine Clinics-specific questions
Get started
Check your marketing.
Start scanning in about 30 seconds.
Unlimited scans. 3 team seats. Founding rate $297/mo locked for life. 30-day money-back guarantee - email support@regencompliance.ai within 30 days for a full refund.
See compliance built for med spas, weight loss clinics, or dental practices. See all specialties
Further reading
Blog posts covering enforcement, claim categories, and tactical playbooks specifically relevant to regenerative medicine clinics.
Stem Cell Marketing: The 5 Phrases That Have Cost Clinics Millions
Stem cell marketing is one of the highest-risk surfaces in healthcare advertising. Five phrases recur in many of the largest settlements against regen-med clinics. This post walks through each one, the regulatory mechanism, and a compliant rewrite that still sells.
Read articleHow a Single Social Media Post Can Become a Multi-Million-Dollar FTC Settlement
Multi-million-dollar FTC settlements against stem cell and regenerative medicine clinics now routinely start with a single Instagram caption or Facebook testimonial. Here is how that chain actually works - and the four places clinics lose control of it.
Read articleFDA Warning Letters at a 25-Year High: What Every Healthcare Practice Needs to Know in 2026
More than 200 FDA warning letters hit healthcare practices in 2024 - the highest volume in a quarter century. Here is what is being flagged, why regenerative medicine and med spas are on the front line, and what a defensible marketing program looks like now.
Read article